Comments
Zydus Cadila has got approval from the US health regulator to market Acylovir drug for injection USP in strengths of 500 mg/vial and 1000 mg/vial. It is used as an anti-viral chiefly in the treatment of herpes and AIDS.
“Zydus Cadila has received final approval from the USFDA to market Acylovir for injection USP in strengths of 500 mg/vial and 1000 mg/vial,” the company said in a BSE filing today.
Acylovir for injection USP caters to the anti-viral segment, the company said, adding that it will be produced at the group’s formulations manufacturing facility at Moraiya, Ahmedabad.
The company said the group has more than 120 approvals and has so far filed over 300 ANDAs (Abbreviated New Drug Application).
Shares of Cadila Healthcare were trading 1.59 per cent higher at Rs 537.25 apiece on the BSE.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.